Metropolis Healthcare Ltd. (IN:METROPOLIS)
:METROPOLIS
Top Page
Metropolis Healthcare Ltd.
(METROPOLIS)
Select Model
Select Model
Rating:61Neutral
Price Target:
₹446.00
▼(-76.89% Downside)
Action:ReiteratedDate:10/10/25
Metropolis Healthcare Ltd. has a strong financial foundation, which is the most significant factor in its overall score. However, technical analysis indicates potential short-term weakness, and the high P/E ratio suggests overvaluation, which detracts from the stock's attractiveness. The absence of earnings call data and corporate events means these factors do not influence the score.
Positive Factors
Strong balance sheet
A very high equity ratio and low debt-to-equity give Metropolis durable financial flexibility. Low leverage reduces refinancing and interest-rate risk, enabling sustained capex for lab expansion, M&A optionality, and the ability to weather demand shocks without diluting shareholders.
Negative Factors
Moderate return on equity
ROE around 10.9% is modest given the company's capital-light diagnostics model and low leverage. This suggests limited efficiency in converting equity into higher shareholder returns, which could constrain long-term per-share value unless operational productivity or pricing power improves.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong balance sheet
A very high equity ratio and low debt-to-equity give Metropolis durable financial flexibility. Low leverage reduces refinancing and interest-rate risk, enabling sustained capex for lab expansion, M&A optionality, and the ability to weather demand shocks without diluting shareholders.
Read all positive factors
Metropolis Healthcare Ltd. (METROPOLIS) vs. iShares MSCI India ETF (INDA)
Market Cap
₹87.69B
Dividend Yield0.21%
Average Volume (3M)3.90K
Price to Earnings (P/E)60.4
Beta (1Y)0.69
Revenue Growth15.41%
EPS Growth5.93%
CountryIN
Employees4,313
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)2.31
Shares Outstanding207,327,770
10 Day Avg. Volume4,604
30 Day Avg. Volume3,901
Financial Highlights & Ratios
PEG Ratio4.05
Price to Book (P/B)5.90
Price to Sales (P/S)5.90
P/FCF Ratio35.81
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)12.56
Revenue Forecast (FY)₹18.73B
Metropolis Healthcare Ltd. Business Overview & Revenue Model
Company Description
Metropolis Healthcare Limited provides diagnostic services in India. It offers clinical laboratory testing, and profiles and support services. The company provides diagnostic services for oncology, neurology, gynecology, and nephrology, as well as...
How the Company Makes Money
Metropolis Healthcare primarily makes money by charging fees for diagnostic tests and allied services. Its main revenue streams typically include: (1) Business-to-consumer (B2C) testing: walk-in and home-collection customers pay for individual tes...
Metropolis Healthcare Ltd. Financial Statement Overview
Summary
Income Statement
85
Very Positive
Balance Sheet
78
Positive
Cash Flow
82
Very Positive
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 14.04B | 13.31B | 12.08B | 11.48B | 12.28B | 9.98B |
| Gross Profit | 10.85B | 10.28B | 9.38B | 8.74B | 9.31B | 7.28B |
| EBITDA | 2.43B | 2.16B | 2.18B | 2.36B | 3.07B | 2.63B |
| Net Income | 1.52B | 1.45B | 1.28B | 1.43B | 2.14B | 1.83B |
Balance Sheet | ||||||
| Total Assets | 0.00 | 18.67B | 15.55B | 15.02B | 15.30B | 10.04B |
| Cash, Cash Equivalents and Short-Term Investments | 1.18B | 1.18B | 1.24B | 1.20B | 1.81B | 4.20B |
| Total Debt | 0.00 | 2.04B | 1.97B | 2.66B | 3.79B | 1.12B |
| Total Liabilities | -13.35B | 5.33B | 4.56B | 5.11B | 6.42B | 2.96B |
| Stockholders Equity | 13.35B | 13.31B | 10.96B | 9.88B | 8.86B | 7.07B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 2.19B | 2.00B | 1.94B | 2.23B | 2.21B |
| Operating Cash Flow | 0.00 | 2.63B | 2.64B | 2.47B | 2.53B | 2.49B |
| Investing Cash Flow | 0.00 | -2.01B | -894.12M | 467.94M | -7.38B | 617.01M |
| Financing Cash Flow | 0.00 | -866.34M | -1.81B | -2.92B | 1.63B | -326.90M |
Metropolis Healthcare Ltd. Technical Analysis
Negative
1929.70
Price Trends
465.60
Negative
474.26
Negative
484.12
Negative
Market Momentum
-11.10
Positive
32.66
Neutral
21.08
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:METROPOLIS, the sentiment is Negative. The current price of 1929.7 is above the 20-day moving average (MA) of 447.75, above the 50-day MA of 465.60, and above the 200-day MA of 484.12, indicating a bearish trend. The MACD of -11.10 indicates Positive momentum. The RSI at 32.66 is Neutral, neither overbought nor oversold. The STOCH value of 21.08 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:METROPOLIS.
Metropolis Healthcare Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | ₹92.03B | 63.11 | ― | 0.20% | 16.71% | 13.92% | |
69 Neutral | ₹58.28B | 61.22 | ― | 0.68% | 22.36% | 52.00% | |
67 Neutral | ₹78.91B | -247.47 | ― | ― | 17.58% | -38.20% | |
66 Neutral | ₹222.73B | 68.44 | ― | 0.89% | 10.80% | 32.79% | |
61 Neutral | ₹87.69B | 60.35 | ― | 0.21% | 15.41% | 5.93% | |
58 Neutral | ₹17.78B | 38.37 | ― | 0.38% | 11.51% | 21.56% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
IN:METROPOLIS
Metropolis Healthcare Ltd.
422.95
52.06
14.04%
IN:HCG
HealthCare Global Enterprises Ltd.
528.50
11.60
2.24%
IN:KRSNAA
Krsnaa Diagnostics Limited
548.05
-182.70
-25.00%
IN:LALPATHLAB
Dr. Lal PathLabs Limited
1,329.30
108.03
8.85%
IN:THYROCARE
Thyrocare Technologies Ltd
366.15
145.09
65.63%
IN:VIJAYA
Vijaya Diagnostic Centre Ltd.
895.85
3.90
0.44%
Metropolis Healthcare Ltd. Corporate Events
Metropolis Healthcare Closes Trading Window Ahead of FY26 Results
Mar 31, 2026
Metropolis Healthcare Ltd. has announced that its trading window for designated persons and their immediate relatives will be closed from April 1, 2026, in line with its code of conduct and SEBI’s insider trading regulations. The window will...
Metropolis Healthcare Boosts Paid-Up Capital with 3-for-1 Bonus Share Issue
Mar 23, 2026
Metropolis Healthcare Ltd. has allotted 155,495,826 bonus equity shares of face value ₹2 each on March 23, 2026, issuing three fully paid shares for every one existing share to eligible shareholders as of the March 20, 2026 record date. Foll...
Metropolis Healthcare Shareholders Approve Bonus Share Issue via E-Voting
Mar 9, 2026
Metropolis Healthcare has secured shareholder approval via a postal ballot and remote e-voting to issue bonus shares, with the resolution passed by the requisite majority. The process was conducted electronically in line with Companies Act provisi...
Metropolis Healthcare Clears Q3 FY26 Results, Announces 3:1 Bonus Issue and Internal Business Transfer
Feb 4, 2026
Metropolis Healthcare Limited’s board has approved the unaudited standalone and consolidated financial results for the quarter and nine months ended 31 December 2025, with the limited review report from its statutory auditors indicating no m...
Metropolis Healthcare Schedules Q3 FY26 Earnings Call for February 5
Jan 30, 2026
Metropolis Healthcare Limited has announced that it will hold its Q3 FY26 earnings conference call on February 5, 2026, at 9:00 a.m. IST, organized by ICICI Securities, to discuss its financial results for the quarter ended December 31, 2025. The ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.